1. Afukozilirovannoe antibody to CD20 with fucose content of 60% or less of the total amount associated with the Asn297 oligosaccharides (sugar) in the treatment of cancer, in combination with an inhibitor MDM2.2. The antibody of claim 1, characterized in that said cancer is a cancer characterized by expression of CD20.3. The antibody of claim 1, characterized in that said cancer is characterized by expression of CD20, is a lymphoma or lymphocytic leykoz.4. The antibody of claim 1, wherein said antibody against CD20 is a humanized antibody B-Ly1.5. The antibody of claim 1, characterized in that said inhibitor MDM2 represents a) 4- [4,5-bis (4-chlorophenyl) -2- (2-isopropoxy-4-methoxy-phenyl) -4,5-dihydro- imidazole-1-carbonyl] -piperazin-2-one, b) (4S, 5R) -1 - [[4 - [[4,5-bis (4-chlorophenyl) -2- [4- (tert-butyl) -2-ethoxy-phenyl] -4,5-dimethyl-4 5-dihydro-1H-imidazol-1-yl]] - carbonyl] -4- [3- (methylsulfonyl) propyl] piperazine, c) 2- {4 - [(4S, 5R) -2- (6-tert butyl-4-ethoxy-pyridin-3-yl) -4,5-bis- (4-chloro-phenyl) -4,5-dimethyl-4,5-dihydro-imidazole-1-carbonyl] -piperazin-1 -yl} -N, N-bis- (2-methoxyethyl) acetamide or d) 2- {1 - [(4S, 5R) -2- (6-tert-butyl-4-ethoxy-pyridin-3-yl) -4,5-bis- (4-chloro-phenyl) -4, 5-dimethyl-4,5-dihydro-imidazole-1-carbonyl] -piperidin-4-yl} -atsetamid.6. An antibody according to any one of claims. 1 to 5, characterized in that the administration is carried out one or more additional other cytotoxic, chemotherapeutic or anticancer agents or compounds or ionizing radiation, the reinforcing action such agentov.7. A composition for treatment of cancer, comprising a humanized antibody B-Ly1,1. Афукозилированное антитело к CD20 с содержанием фукозы 60% или менее от общего количества связанных с Asn297 олигосахаридов (сахаров) для лечения рака, в сочетании с ингибитором MDM2.2. Антитело по п.1, отличающееся тем, что указанный рак представляет собой рак, характеризующийся экспрессией CD20.3. Антитело по п.1, отличающееся тем, что указан
